This study supports the fact that SCT recipients are at significant longterm risk for the development of secondary solid tumors. Further longer term reports from larger cohorts of SCT recipients are needed to better define overall risk over time. It is important for patients and their physicians to be aware of these risks to modify screening and preventative techniques in this patient population. an effort to limit transplant related toxicity and broaden potential treatment options for older and sicker patient populations. The role of pretransplant consolidative chemotherapy may be different in the RIC-SCT setting than the myeloablative setting. One could hypothesize that with less intensive conditioning therapy, additional rounds of cytarabine-based consolidation chemotherapy before RIC-SCT would result in lower relapse rates by minimizing residual disease. Alternatively, RIC-SCT recipients tend to be older and sicker than myeloablative SCT recipients and increased rounds of therapy before SCT may contribute to more treatment-related mortality.